Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Clinical trial NCT03302728 · COMPLETED

Trial details

NCT number: NCT03302728
Sponsor: Peter MacCallum Cancer Centre, Australia
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, T-Cell, Cutaneous Lymphoma, T-Cell, Peripheral Hodgkin Lymphoma

Start date: 2018-08-30
Primary completion: 2021-08-02
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.